Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 20/20 | 0.71 |
| ▸ | DDB1 | Q16531 | 6/20 | 0.71 |
| ▸ | IKZF3 | Q9UKT9 | 1/20 | 0.71 |
| ▸ | GSPT1 | P15170 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5743565 | 0.86 | CRBN (0.71) | CRBNDDB1IKZF3GSPT1 | |
| SCHEMBL24966246 | 0.86 | CRBN (0.69) | CRBNDDB1IKZF3GSPT1 | |
| SCHEMBL20772911 | 0.86 | CRBN (0.75) | CRBNDDB1IKZF3GSPT1 | |
| SCHEMBL24890988 | 0.86 | CRBN (0.75) | CRBNDDB1IKZF3GSPT1 | |
| SCHEMBL20772960 | 0.86 | CRBN (0.75) | CRBNDDB1IKZF3GSPT1 | |
| SCHEMBL25290137 | 0.85 | CRBN (0.65) | CRBNDDB1IKZF3GSPT1 | |
| SCHEMBL25290471 | 0.85 | CRBN (0.81) | CRBNDDB1IKZF3GSPT1 | |
| SCHEMBL19586515 | 0.85 | CRBN (0.77) | CRBNDDB1IKZF3GSPT1 | |
| SCHEMBL29179885 | 0.83 | CRBN (1.00) | CRBNDDB1IKZF3 | |
| SCHEMBL19586538 | 0.83 | CRBN (0.75) | CRBNDDB1IKZF3GSPT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240199638-A1 | GLUTARIMIDES FOR MEDICAL TREATMENT | C4 THERAPEUTICS, INC. (US) | 2024-06-20 | — | — | US | disclosed |
| CN-118108706-A | Glutarimide | C4医药公司 | 2024-05-31 | — | — | CN | disclosed |
| CN-111278815-B | Glutarimide | C4医药公司 | 2024-03-08 | — | — | CN | disclosed |
| US-11802131-B2 | Glutarimides for medical treatment | C4 THERAPEUTICS, INC. (US) | 2023-10-31 | — | — | US | disclosed |
| US-20200207783-A1 | GLUTARIMIDES FOR MEDICAL TREATMENT | C4 THERAPEUTICS, INC. (US) | 2020-07-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11802131-B2 | Glutarimides for medical treatment | CRBN, GCDH, GCLC | CRBN 1/4885DDB1 414/4885IKZF3 1768/4885 |
| US-20240199638-A1 | GLUTARIMIDES FOR MEDICAL TREATMENT | CRBN, GCDH, GCLC | CRBN 1/4885DDB1 414/4885IKZF3 1768/4885 |
| US-20200207783-A1 | GLUTARIMIDES FOR MEDICAL TREATMENT | CRBN, GCDH, GCLC | CRBN 1/4885DDB1 414/4885IKZF3 1768/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.